Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Vitamin E Increases Antimicrobial Sensitivity by Inhibiting Bacterial Lipocalin Antibiotic Binding.

Naguib MM, Valvano MA.

mSphere. 2018 Dec 12;3(6). pii: e00564-18. doi: 10.1128/mSphere.00564-18.

2.

CHARMM-GUI Membrane Builder for Complex Biological Membrane Simulations with Glycolipids and Lipoglycans.

Lee J, Patel DS, Ståhle J, Park SJ, Kern NR, Kim SH, Lee J, Cheng X, Valvano MA, Holst O, Knirel YA, Qi Y, Jo S, Klauda JB, Widmalm G, Im W.

J Chem Theory Comput. 2018 Dec 11. doi: 10.1021/acs.jctc.8b01066. [Epub ahead of print]

PMID:
30525595
3.

Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer.

Tavano F, Gioffreda D, Valvano MR, Palmieri O, Tardio M, Latiano TP, Piepoli A, Maiello E, Pirozzi F, Andriulli A.

Sci Rep. 2018 Nov 6;8(1):16389. doi: 10.1038/s41598-018-34597-z.

4.

Complex Signaling Networks Controlling Dynamic Molecular Changes in Pseudomonas aeruginosa Biofilm.

Gula G, Dorotkiewicz-Jach A, Korzekwa K, Valvano MA, Drulis-Kawa Z.

Curr Med Chem. 2018 Sep 11. doi: 10.2174/0929867325666180912110151. [Epub ahead of print]

PMID:
30207213
5.

The ArcAB two-component regulatory system promotes resistance to reactive oxygen species and systemic infection by Salmonella Typhimurium.

Pardo-Esté C, Hidalgo AA, Aguirre C, Briones AC, Cabezas CE, Castro-Severyn J, Fuentes JA, Opazo CM, Riedel CA, Otero C, Pacheco R, Valvano MA, Saavedra CP.

PLoS One. 2018 Sep 4;13(9):e0203497. doi: 10.1371/journal.pone.0203497. eCollection 2018.

6.

Escherichia coli and Pseudomonas aeruginosa lipopolysaccharide O-antigen ligases share similar membrane topology and biochemical properties.

Ruan X, Monjarás Feria J, Hamad M, Valvano MA.

Mol Microbiol. 2018 Oct;110(1):95-113. doi: 10.1111/mmi.14085. Epub 2018 Oct 3.

PMID:
30047569
7.

Cultural Change: Implementation of a Recovery Program in a Veterans Health Administration Medical Center Inpatient Unit.

McDonagh JG, Haren WB, Valvano M, Grubaugh AL, Wainwright FC, Rhue CH, Pelic CM, Pelic CG, Koval R, York JA.

J Am Psychiatr Nurses Assoc. 2018 Jul 1:1078390318786024. doi: 10.1177/1078390318786024. [Epub ahead of print]

PMID:
29973093
8.

Metabolic disorders across hepatocellular carcinoma in Italy.

Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group.

Liver Int. 2018 Nov;38(11):2028-2039. doi: 10.1111/liv.13877. Epub 2018 Jun 19.

PMID:
29745475
9.

Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3.

Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium.

United European Gastroenterol J. 2018 Mar;6(2):225-237. doi: 10.1177/2050640617717158. Epub 2017 Jun 20.

10.

Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas.

Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, Grossi A, Brancaccio G, Coco C, Russello M, Smedile A, Petrini E, Martini S, Gaeta GB, Rizzetto M.

Eur J Intern Med. 2018 Jul;53:79-84. doi: 10.1016/j.ejim.2018.02.015. Epub 2018 Feb 21.

PMID:
29475770
11.

Novel antibiotic combinations proposed for treatment of Burkholderia cepacia complex infections.

El-Halfawy OM, Naguib MM, Valvano MA.

Antimicrob Resist Infect Control. 2017 Nov 25;6:120. doi: 10.1186/s13756-017-0279-8. eCollection 2017.

12.

Hepatitis C Virus Clearance in Older Adults.

Ippolito AM, Iacobellis A, Milella M, Conti F, Messina V, Valvano MR, Niro GA, Morisco F, Barone M, Termite AP, Brancaccio G, Andriulli A.

J Am Geriatr Soc. 2018 Jan;66(1):85-91. doi: 10.1111/jgs.15140. Epub 2017 Nov 14.

PMID:
29135030
13.

Subfunctionalization influences the expansion of bacterial multidrug antibiotic resistance.

Perrin E, Fondi M, Bosi E, Mengoni A, Buroni S, Scoffone VC, Valvano M, Fani R.

BMC Genomics. 2017 Oct 30;18(1):834. doi: 10.1186/s12864-017-4222-4.

14.

Structure of O-Antigen and Hybrid Biosynthetic Locus in Burkholderia cenocepacia Clonal Variants Recovered from a Cystic Fibrosis Patient.

Hassan AA, Maldonado RF, Dos Santos SC, Di Lorenzo F, Silipo A, Coutinho CP, Cooper VS, Molinaro A, Valvano MA, Sá-Correia I.

Front Microbiol. 2017 Jun 8;8:1027. doi: 10.3389/fmicb.2017.01027. eCollection 2017.

15.

HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.

Ippolito AM, Milella M, Messina V, Conti F, Cozzolongo R, Morisco F, Brancaccio G, Barone M, Santantonio T, Masetti C, Tundo P, Smedile A, Carretta V, Gatti P, Termite AP, Valvano MR, Bruno G, Fabrizio C, Andreone P, Zappimbulso M, Gaeta GB, Napoli N, Fontanella L, Lauletta G, Cuccorese G, Metrangolo A, Francavilla R, Ciracì E, Rizzo S, Andriulli A.

Dig Liver Dis. 2017 Sep;49(9):1022-1028. doi: 10.1016/j.dld.2017.03.025. Epub 2017 Apr 8.

16.

Phage Life Cycles Behind Bacterial Biodiversity.

Olszak T, Latka A, Roszniowski B, Valvano MA, Drulis-Kawa Z.

Curr Med Chem. 2017 Nov 24;24(36):3987-4001. doi: 10.2174/0929867324666170413100136. Review.

PMID:
28412903
17.

Antibiotic Capture by Bacterial Lipocalins Uncovers an Extracellular Mechanism of Intrinsic Antibiotic Resistance.

El-Halfawy OM, Klett J, Ingram RJ, Loutet SA, Murphy ME, Martín-Santamaría S, Valvano MA.

MBio. 2017 Mar 14;8(2). pii: e00225-17. doi: 10.1128/mBio.00225-17.

18.

Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.

Guarino M, Morisco F, Valvano MR, Ippolito AM, Librandi M, Andriulli N, Greco M, Amoruso A, Iacobellis A, Niro G, Caporaso N, Andriulli A.

Aliment Pharmacol Ther. 2017 May;45(9):1193-1200. doi: 10.1111/apt.14017. Epub 2017 Mar 6. Review.

19.

The LpxL acyltransferase is required for normal growth and penta-acylation of lipid A in Burkholderia cenocepacia.

Fathy Mohamed Y, Hamad M, Ortega XP, Valvano MA.

Mol Microbiol. 2017 Apr;104(1):144-162. doi: 10.1111/mmi.13618. Epub 2017 Jan 27.

20.

Crohn's Disease Localization Displays Different Predisposing Genetic Variants.

Palmieri O, Bossa F, Valvano MR, Corritore G, Latiano T, Martino G, D'Incà R, Cucchiara S, Pastore M, D'Altilia M, Scimeca D, Biscaglia G, Andriulli A, Latiano A.

PLoS One. 2017 Jan 4;12(1):e0168821. doi: 10.1371/journal.pone.0168821. eCollection 2017.

21.

Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia.

Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, Siena D, Caruso M, Ippolito A, Mannuccio PM, Andriulli A.

Eur J Intern Med. 2017 Mar;38:79-82. doi: 10.1016/j.ejim.2016.11.007. Epub 2016 Dec 15.

PMID:
27989373
22.

The Burkholderia cenocepacia peptidoglycan-associated lipoprotein is involved in epithelial cell attachment and elicitation of inflammation.

Dennehy R, Romano M, Ruggiero A, Mohamed YF, Dignam SL, Mujica Troncoso C, Callaghan M, Valvano MA, Berisio R, McClean S.

Cell Microbiol. 2017 May;19(5). doi: 10.1111/cmi.12691. Epub 2016 Nov 25.

PMID:
27886433
23.

The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage.

Roszniowski B, Latka A, Maciejewska B, Vandenheuvel D, Olszak T, Briers Y, Holt GS, Valvano MA, Lavigne R, Smith DL, Drulis-Kawa Z.

Appl Microbiol Biotechnol. 2017 Feb;101(3):1203-1216. doi: 10.1007/s00253-016-7924-7. Epub 2016 Oct 21.

24.

HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.

Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, Zachou K, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M.

Aliment Pharmacol Ther. 2016 Sep;44(6):620-8. doi: 10.1111/apt.13734. Epub 2016 Jul 22.

25.

Analysis of clock gene-miRNA correlation networks reveals candidate drivers in colorectal cancer.

Mazzoccoli G, Colangelo T, Panza A, Rubino R, Tiberio C, Palumbo O, Carella M, Trombetta D, Gentile A, Tavano F, Valvano MR, Storlazzi CT, Macchia G, De Cata A, Bisceglia G, Capocefalo D, Colantuoni V, Sabatino L, Piepoli A, Mazza T.

Oncotarget. 2016 Jul 19;7(29):45444-45461. doi: 10.18632/oncotarget.9989.

26.

Transperineal ultrasonography: First level exam in IBD patients with perianal disease.

Terracciano F, Scalisi G, Bossa F, Scimeca D, Biscaglia G, Mangiacotti M, Valvano MR, Perri F, Simeone A, Andriulli A.

Dig Liver Dis. 2016 Aug;48(8):874-9. doi: 10.1016/j.dld.2016.03.027. Epub 2016 Apr 26.

PMID:
27185514
27.

A Burkholderia Type VI Effector Deamidates Rho GTPases to Activate the Pyrin Inflammasome and Trigger Inflammation.

Aubert DF, Xu H, Yang J, Shi X, Gao W, Li L, Bisaro F, Chen S, Valvano MA, Shao F.

Cell Host Microbe. 2016 May 11;19(5):664-74. doi: 10.1016/j.chom.2016.04.004. Epub 2016 Apr 28.

28.

Lipopolysaccharide modification in Gram-negative bacteria during chronic infection.

Maldonado RF, Sá-Correia I, Valvano MA.

FEMS Microbiol Rev. 2016 Jul;40(4):480-93. doi: 10.1093/femsre/fuw007. Epub 2016 Apr 12. Review.

29.

Deregulated expression of cryptochrome genes in human colorectal cancer.

Mazzoccoli G, Colangelo T, Panza A, Rubino R, De Cata A, Tiberio C, Valvano MR, Pazienza V, Merla G, Augello B, Trombetta D, Storlazzi CT, Macchia G, Gentile A, Tavano F, Vinciguerra M, Bisceglia G, Rosato V, Colantuoni V, Sabatino L, Piepoli A.

Mol Cancer. 2016 Jan 15;15:6. doi: 10.1186/s12943-016-0492-8.

30.

Tyrosine Phosphorylation and Dephosphorylation in Burkholderia cenocepacia Affect Biofilm Formation, Growth under Nutritional Deprivation, and Pathogenicity.

Andrade A, Tavares-Carreón F, Khodai-Kalaki M, Valvano MA.

Appl Environ Microbiol. 2015 Nov 20;82(3):843-56. doi: 10.1128/AEM.03513-15. Print 2016 Feb 1.

31.

ArnT proteins that catalyze the glycosylation of lipopolysaccharide share common features with bacterial N-oligosaccharyltransferases.

Tavares-Carreón F, Fathy Mohamed Y, Andrade A, Valvano MA.

Glycobiology. 2016 Mar;26(3):286-300. doi: 10.1093/glycob/cwv095. Epub 2015 Oct 29.

32.

Quantification of type VI secretion system activity in macrophages infected with Burkholderia cenocepacia.

Aubert DF, Hu S, Valvano MA.

Microbiology. 2015 Nov;161(11):2161-73. doi: 10.1099/mic.0.000174. Epub 2015 Sep 11.

PMID:
26364149
33.

Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains.

Cullen L, Weiser R, Olszak T, Maldonado RF, Moreira AS, Slachmuylders L, Brackman G, Paunova-Krasteva TS, Zarnowiec P, Czerwonka G, Reilly J, Drevinek P, Kaca W, Melter O, De Soyza A, Perry A, Winstanley C, Stoitsova SR, Lavigne R, Mahenthiralingam E, Sá-Correia I, Coenye T, Drulis-Kawa Z, Augustyniak D, Valvano MA, McClean S.

Microbiology. 2015 Oct;161(10):1961-77. doi: 10.1099/mic.0.000155. Epub 2015 Aug 6.

PMID:
26253522
34.

Intracellular survival of Burkholderia cepacia complex in phagocytic cells.

Valvano MA.

Can J Microbiol. 2015 Sep;61(9):607-15. doi: 10.1139/cjm-2015-0316. Epub 2015 Jun 30.

35.

Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia.

Loutet SA, El-Halfawy OM, Jassem AN, López JM, Medarde AF, Speert DP, Davies JE, Valvano MA.

Int J Antimicrob Agents. 2015 Oct;46(4):376-80. doi: 10.1016/j.ijantimicag.2015.05.010. Epub 2015 Jun 22.

PMID:
26187366
36.

Activation of Human Toll-like Receptor 4 (TLR4)·Myeloid Differentiation Factor 2 (MD-2) by Hypoacylated Lipopolysaccharide from a Clinical Isolate of Burkholderia cenocepacia.

Di Lorenzo F, Kubik Ł, Oblak A, Lorè NI, Cigana C, Lanzetta R, Parrilli M, Hamad MA, De Soyza A, Silipo A, Jerala R, Bragonzi A, Valvano MA, Martín-Santamaría S, Molinaro A.

J Biol Chem. 2015 Aug 28;290(35):21305-19. doi: 10.1074/jbc.M115.649087. Epub 2015 Jul 9.

37.

Burkholderia cenocepacia Lipopolysaccharide Modification and Flagellin Glycosylation Affect Virulence but Not Innate Immune Recognition in Plants.

Khodai-Kalaki M, Andrade A, Fathy Mohamed Y, Valvano MA.

MBio. 2015 Jun 4;6(3):e00679. doi: 10.1128/mBio.00679-15.

39.

Renal tuberculosis: a case report.

Toccaceli S, Persico Stella L, Diana M, Taccone A, Giuliani G, De Paola L, Valvano M, De Padua C, Di Biasio G, Ranucci C, Orsi E, La Torre F.

G Chir. 2015 Mar-Apr;36(2):76-8.

40.

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

Andriulli A, Morisco F, Ippolito AM, Di Marco V, Valvano MR, Angelico M, Fattovich G, Granata R, Smedile A, Milella M, Felder M, Gaeta GB, Gatti P, Fasano M, Mazzella G, Santantonio T.

Hepatol Int. 2015 Jan;9(1):52-7. doi: 10.1007/s12072-014-9556-2. Epub 2014 Aug 13.

41.
42.

Role of capsular modified heptose in the virulence of Campylobacter jejuni.

Wong A, Lange D, Houle S, Arbatsky NP, Valvano MA, Knirel YA, Dozois CM, Creuzenet C.

Mol Microbiol. 2015 Jun;96(6):1136-58. doi: 10.1111/mmi.12995. Epub 2015 Apr 11.

43.

Antimicrobial heteroresistance: an emerging field in need of clarity.

El-Halfawy OM, Valvano MA.

Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14. Review.

44.

Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.

Palmieri O, Ippolito AM, Margaglione M, Valvano MR, Gioffreda D, Fasano M, D'Andrea G, Corritore G, Milella M, Andriulli N, Morisco F, Giannitrapani L, Latiano A, Fontana R, Gatti P, Tundo P, Barone M, Cozzolongo R, Santantonio T, Andriulli A.

Liver Int. 2014 Oct;34(9):1369-77. doi: 10.1111/liv.12411. Epub 2013 Dec 23.

PMID:
25283962
45.

A markerless deletion method for genetic manipulation of Burkholderia cenocepacia and other multidrug-resistant gram-negative bacteria.

Aubert DF, Hamad MA, Valvano MA.

Methods Mol Biol. 2014;1197:311-27. doi: 10.1007/978-1-4939-1261-2_18.

PMID:
25172289
46.

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators.

Dig Liver Dis. 2014 Sep;46(9):818-25. doi: 10.1016/j.dld.2014.05.015. Epub 2014 Jun 20.

PMID:
24953209
47.

Elucidation of the Burkholderia cenocepacia hopanoid biosynthesis pathway uncovers functions for conserved proteins in hopanoid-producing bacteria.

Schmerk CL, Welander PV, Hamad MA, Bain KL, Bernards MA, Summons RE, Valvano MA.

Environ Microbiol. 2015 Mar;17(3):735-50. doi: 10.1111/1462-2920.12509. Epub 2014 Jun 24.

PMID:
24888970
48.

Identification of the flagellin glycosylation system in Burkholderia cenocepacia and the contribution of glycosylated flagellin to evasion of human innate immune responses.

Hanuszkiewicz A, Pittock P, Humphries F, Moll H, Rosales AR, Molinaro A, Moynagh PN, Lajoie GA, Valvano MA.

J Biol Chem. 2014 Jul 4;289(27):19231-44. doi: 10.1074/jbc.M114.562603. Epub 2014 May 19.

49.

Putrescine reduces antibiotic-induced oxidative stress as a mechanism of modulation of antibiotic resistance in Burkholderia cenocepacia.

El-Halfawy OM, Valvano MA.

Antimicrob Agents Chemother. 2014 Jul;58(7):4162-71. doi: 10.1128/AAC.02649-14. Epub 2014 May 12.

50.

miRNAs for the detection of multidrug resistance: overview and perspectives.

Gisel A, Valvano M, El Idrissi IG, Nardulli P, Azzariti A, Carrieri A, Contino M, Colabufo NA.

Molecules. 2014 Apr 30;19(5):5611-23. doi: 10.3390/molecules19055611.

Supplemental Content

Loading ...
Support Center